AUROLAB

Auro Laboratories Ltd.

BSE: 530233

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

236.55+0.1 (+0.04%)

9 Oct, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

18.1 / 100

Value Score

42.9 / 100

Price Momentum Score

50.7 / 100

QVM Score

21.2 / 100

Key Metrics

Market Cap

147.44

P/E (TTM)

31.48

P/B

3.18

P/S (TTM)

4.00

EV/EBITDA

15.98

CAPE (5Y)

40.04

ROE (TTM)

7.91

ROCE (TTM)

7.28

ROA (TTM)

3.21

Avg 3Y ROE

10.90

Earnings 3Y CAGR

15.23

Sales 3Y CAGR

-10.80

Sales 5Y CAGR

-6.86

Debt/Equity

1.37

Consensus TP

Strong Buy %

Promoter Holding

52.40

Pledged %

0.00

Stock Analysis

Fundamental analysis overview of Auro Laboratories Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

High and improving operating margin

The company reported strong operating margin of 26.16% for 12-month ended 30 Jun 2026 and operating margin improved by 1989 bps from 1 year ago

What is Operating profit margin?

Strong revenue growth and above median growth of industry

The company delivered strong revenue growth of 123.63% for 12-month ended 30 Jun 2026 and the growth was 112.95 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 10.68

Value 123.63

-99.6111701.8

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 388.44% for 12-month ended 30 Jun 2026 and the growth was 380.99 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Negative

Expensive and at same valuation levels as industry median P/E

PE TTM of 31.48 indicates that the stock is expensive on a standalone basis. Discount to industry median P/E is modest at 0.0%

What is P/E Ratio?

Median: 31.48

Value 31.48

-0.8734.68

Reasonable Debt to Equity, but increasing

The company has reasonable Debt to Equity of 1.37 as on 30 Jun 2026 but Debt to Equity increased by 0.32 in the last 1 year

What is Debt to Equity?

Company's earnings are of low quality

Earnings quality score of 29.8 indicates that the company's earnings are of low quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

29.8 / 100

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Low ROE but improving trend

The company reported low ROE of 7.91% for 12-month ended 30 Jun 2026 but ROE improved by 357 bps from 1 year ago

What is ROE (FY)?

Financial Snapshot

See detailed analysis

Multi-year trends for Auro Laboratories Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Auro Laboratories Ltd. Shareholding Pattern

Quarterly breakdown of Auro Laboratories Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Total Promoter	51.92	51.92	51.92	51.92	51.92	51.92	51.93	51.99	51.99	52.09	52.09	52.09	52.09	52.09	52.09	52.09	52.15	52.15	52.15	52.15	52.18	52.18	52.18	52.18	52.18	52.40
Indian Promoter	51.92	51.92	51.92	51.92	51.92	51.92	51.93	51.99	51.99	52.09	52.09	52.09	52.09	52.09	52.09	52.09	52.15	52.15	52.15	52.15	52.18	52.18	52.18	52.18	52.18	52.40
Foreign Promoter	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Institutions	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Mutual Funds / UTI	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
FI/Bank/Insurance	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Govt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
FII	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Other Institutions	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Institution	48.07	48.07	48.07	48.07	48.07	48.07	48.06	48.00	48.00	47.90	47.90	47.90	47.90	47.90	47.90	47.90	47.84	47.84	47.84	47.84	47.82	47.82	47.82	47.82	47.82	47.59
Bodies Corporate	0.81	0.80	0.88	0.74	0.61	1.15	1.32	1.37	0.72	0.74	0.80	0.86	0.84	0.82	2.13	2.14	2.29	2.01	1.97	1.71	1.18	1.39	1.53	1.68	1.70	1.24
Others (incl. Retail) No. of shareholders	47.26 7,136	47.27 7,417	47.19 7,762	47.33 8,089	47.46 9,114	46.92 9,332	46.74 10,086	46.63 10,144	47.28 11,297	47.16 11,320	47.10 11,142	47.04 11,094	47.06 10,865	47.08 10,461	45.77 10,231	45.76 9,862	45.55 9,399	45.83 9,296	45.87 9,227	46.13 9,231	46.64 9,068	46.43 8,880	46.29 8,824	46.14 8,602	46.12 8,368	46.35 8,281

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Auro Laboratories Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Siddhartha Deorah Promoter	October-2021	Market Purchase (Acquisition) 1st Oct 2021	6.93 %	₹ 121.19	1.00 k	₹ 1.21 lac
Siddhartha Deorah Promoter	September-2021	Market Purchase (Acquisition) 18th Sep 2021	6.92 %	₹ 126.40	200.00	₹ 25.28 k
Siddhartha Deorah Promoter	September-2021	Market Purchase (Acquisition) 18th Sep 2021	6.92 %	₹ 121.40	500.00	₹ 60.70 k

No corporate action data available.

Company Profile

Overview of Auro Laboratories Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Auro Laboratories Limited is an India-based company, which is engaged in the manufacturing activities of active pharmaceutical ingredients (APIs). The Company is specializing in producing anti-diabetics like Metformin HCL, which is used in the treatment of type 2 diabetes. It also undertakes toll/cu...

Key personnel

Mr. Nitesh Bohra

Chief Financial Officer

Ms. Padma Tapariya

Compliance Officer, Company Secretary

Sharat DeorahD

Executive Chairman of the Board, Managing Director

Mr. Siddhartha DeorahD

Whole-Time Director

Mr. Kiran Suresh KulkarniD

Whole Time Director

Mr. Mahendra Kumar DagaD

Additional Non-Executive Independent Director

Mr. Vishal Kailashchandra JhunjhunwalaD

Additional Non-Executive Independent Director

Mrs. Kavita Vijayakant SharmaD

Non-Executive Independent Director

Incorporated on

26 May 1989

Last Annual

31 Mar 2026

Last Interim

30 Jun 2026

No. of Employees

IPO date

07 Mar 1995

Free Float

24,78,575

Website

https://www.aurolabs.com/

Phone no.

+912266635456

Address

314, T.V. INDUSTRIAL ESTATE, S.K. AHIRE MARG,, WORLI, , 400030, India

Frequently Asked Questions

What is the current share price of Auro Laboratories Ltd.?

The current share price of Auro Laboratories Ltd. is ₹ 236.55 as of 9 Oct 2026.

What is the market capitalisation of Auro Laboratories Ltd.?

The market capitalisation of Auro Laboratories Ltd. stands at ₹ 147.44 Cr.

What is the PE ratio of Auro Laboratories Ltd.?

The Price-to-Earnings (PE) ratio of Auro Laboratories Ltd. is 31.48 as of the latest trailing twelve months data.

What is the ROE and ROCE of Auro Laboratories Ltd.?

Auro Laboratories Ltd. has a Return on Equity (ROE) of 7.91% and a Return on Capital Employed (ROCE) of 7.28% as per the latest financial reports.

What is the 52-week high and low of Auro Laboratories Ltd.?

The 52-week high of Auro Laboratories Ltd. is - and the 52-week low is -.

What is the dividend yield of Auro Laboratories Ltd.?

The dividend yield of Auro Laboratories Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Auro Laboratories Ltd.?

Foreign Institutional Investors (FII) hold 0.00%, Domestic Institutional Investors (DII) hold 0.01% and retail/public investors hold 46.35% of Auro Laboratories Ltd. shares.

What sector does Auro Laboratories Ltd. belong to?

Auro Laboratories Ltd. operates in the Healthcare sector.

What is the beta of Auro Laboratories Ltd.?

The beta of Auro Laboratories Ltd. is 0.91, indicating its price volatility relative to the broader market. Over the past 1 year, Auro Laboratories Ltd. has delivered an absolute return of -0.71%.

What is the RSI of Auro Laboratories Ltd.?

The 14-day Relative Strength Index (RSI) of Auro Laboratories Ltd. is 45.13, placing it in the neutral zone. An RSI above 70 is considered overbought and below 30 is considered oversold.

Auro Laboratories Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Auro Laboratories Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile